Upside, Downside Movers in the Morning

Avatar photo Doug Kass on October 1, 2026

Upside

– $MEDS +36% (preliminary September pharmacy revenue exceeded $1M, rising more than 66% from July)

– $ACN +17% (Q4 beat with $22.2B of bookings and stronger operating margins)

– $ABAT +13% (receives federal approval to export up to $100M of recycled black-mass material)

– $QSI +13% (no clear fresh catalyst identified; unusually large move on heavy premarket volume)

– $VICR +12% (raises Q3 sequential revenue-growth outlook to more than 30% from more than 20% on higher royalties)

– $GLOB +11%, $CTSH +7.5%, $INFY +8.1%, $EPAM +6.6% (IT-services names rise in read-through from ACN’s Q4 beat, strong bookings and margin performance)

– $INSG +9.6% (completes fixed-wireless-access acquisition expected to roughly double revenue and expand its global footprint)

– $IBM +5.7% (unveils a self-hosted enterprise AI model)

– $NU +5.6% (rebounds after clarifying it is not pursuing the reported UK digital-bank acquisition)

– $GLUE +4.8% (Phase 1 GFORCE-1 results showed normalization of key pathogenic drivers of cardiovascular disease)

– $RKLB +4.3% (signs its largest commercial launch agreement, covering 20 missions and lifting total backlog above 100 launches)

– $MKC +3.7% (Q3 profit and sales beat expectations as pricing offset softer volumes)

– $SNPS +3.7% (signs a multiyear silicon-IP and engineering-software agreement valued above $1B)

– $CEG +3.4% (signs a 20-year, 690-megawatt nuclear power agreement supporting more than $3B of infrastructure investment)

– $TARA +3.3% (updated 12-month Phase 2 ADVANCED-2 data showed durable responses in BCG-naïve bladder-cancer patients)

Downside

– $FHTX -43% (Phase 1 review leads to discontinuation of FHD-909 expansion and a related degrader program; workforce cut about 40%)

– $ANGO -16% (no clear fresh catalyst identified; unusually large, high-volume premarket decline)

– $LQDA -12% (federal court rules YUTREPIA infringed two pulmonary-hypertension patent claims)

– $ZELA -12% (Phase 3 obesity trial met its endpoints, but weight-loss efficacy fell short of investor expectations)

– $BGIN -10% (slides following first-half results)

– $IVA -10% (extends weakness following unaudited first-half results and corporate update)

– $FLOC -8.5% (no clear fresh catalyst identified; unusually large, liquid premarket decline)

– $ENTX -6.4% (no clear fresh catalyst identified after healthcare and company-news checks)